Arbitration: considerations for life science companies
October 2019
In the second instalment of our Life Sciences Disputes webinar series, Arbitration: considerations for life science companies, we provide practical tips and advice, discuss key legislation and share case studies on how life sciences organisations can mitigate and manage their litigation risk.
Topics covered in the webinar include:
- What subject matter can be arbitrated and how arbitration may arise?
- Typical advantages/disadvantages of arbitration versus litigation.
- Industry-specific points for parties in the life sciences considering arbitration.
- Arbitration proceedings rules, tribunal composition, location and choice of law.
- Decisions, remedies, enforcement and challenges.
If you have any questions on this article or would like to propose a subject to be addressed by Synapse please contact us.
Latest topical issues
Taking a new approach to European patent law 
New draft regulations on advertising of medical devices in Poland
Patenting of gene and protein sequences: an EU and US perspective
Previous articles
IP, divestments, fragmentation and the future: M&A in life science
Chris Thornham
Chris is a partner in the London office, specialising in patents and technical disputes.
Laurence Lieberman
Laurence is a partner in the London office, specialising in litigation, international arbitration and regulatory and corporate investigations.
Colin McCall
Colin is a senior counsel in the London office, specialising in life sciences and technology.